Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,581.00
(
1.15%
)
US TECH 100
23,579.34
(
1.28%
)
Dow Jones
46,208.47
(
1.38%
)
Brent Oil
100.53
(
3.86%
)
Bitcoin
70,405.00
(
-0.70%
)
News Focus
News Focus
Post# of 257273
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122807
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dav1234 post# 140437

Thursday, 04/19/2012 8:49:52 AM

Thursday, April 19, 2012 8:49:52 AM

Post# of 257273

BMY trades 2.2% higher premarket after the company releases data today at the European Association for the Study of Liver Disease (EASL) annual meeting showing strong data on its GS-7977 Hepatitis C candidate.

Error in that news blurb insofar as GS7977 is not BMY’s drug. What the blurb meant to say is that the regimen of GS7977 plus BMY’s NS5A inhibitor, daclatasvir, produced a 100% SVR rate.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today